Compass Therapeutics Inc.
CMPX
NASDAQ
Biotechnology
$2.25
USD
-0.01 (-0.44%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $407.00M
Volume 1.4M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-73.45M
TTM
-18.4%
YoY
Operating Cash Flow
$-56.11M
TTM
-24.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.7 | 3.0 | 4.3 | 6.9 | 7.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 21.1 | 15.8 | 18.0 | 20.3 | 27.0 |
Operating Income | -21.1 | -15.8 | -18.0 | -20.3 | -27.0 |
EBITDA | -21.0 | -15.8 | -18.0 | -20.3 | -27.0 |
Other Income / Expense | 1.2 | 1.6 | 2.3 | 2.0 | 1.8 |
Total Other Income / Expense | 1.2 | 1.6 | 2.3 | 2.0 | 1.8 |
Income Before Income Taxes | -19.9 | -14.3 | -15.7 | -18.3 | -25.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -19.9 | -14.3 | -15.7 | -18.3 | -25.2 |
Consolidated Net Income / Loss | -19.9 | -14.3 | -15.7 | -18.3 | -25.2 |
Net Income Attributable to Common Shareholders | -19.9 | -14.3 | -15.7 | -18.3 | -25.2 |
Basic EPS | -$0.14 | -$0.08 | -$0.08 | -$0.10 | -$0.13 |
Diluted EPS | -$0.14 | -$0.08 | -$0.08 | -$0.10 | -$0.13 |
Basic Shares Outstanding | 138.3M | 168.8M | 185.5M | 186.4M | 186.8M |
Diluted Shares Outstanding | 138.3M | 168.8M | 185.5M | 186.4M | 186.8M |